First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Pfizer To Know Covid Shot’s Efficacy Against Omicron...

Newsdeck

Pfizer's Omicron efficacy

Pfizer To Know Covid Shot’s Efficacy Against Omicron Before Year-End

A healthcare worker prepares a Pfizer-BioNTech vaccine for Covid-19 at a vaccination center in Munich, Germany, on Thursday, Dec. 2, 2021. Germany is poised to clamp down on people who aren’t vaccinated against Covid-19 and drastically curtail social contacts to ease pressure on increasingly stretched hospitals. Photographer: Michaela Handrek-Rehle/Bloomberg
By Bloomberg
08 Dec 2021 0

(Bloomberg) -- Pfizer Inc. will have data telling how well its vaccine prevents infections with the omicron variant before the end of the year, Chief Executive Officer Albert Bourla said. 

By Riley Griffin

Word Count: 423
The company is looking to data on the vaccine’s performance from health providers and other sources to give a clearer picture of effectiveness, Bourla said Wednesday in an interview on Bloomberg Television’s “Balance of Power With David Westin.”

“What I really think will be the final verdict will be the real-world data,” he  said. “We are expecting to see those toward the end of the year.”

On Wednesday, Pfizer and partner BioNTech SE released results of laboratory experiments on the highly transmissible variant’s evasion of vaccines that were obtained with a construct called a pseudovirus, Bourla said. The company is still working with the real virus while collecting evidence on how the vaccine performs in community use, he said.

The CEO expects that a third booster dose will “do the job” in restoring high levels of protection. That will likely accelerate booster-shot drives around the world and may buy time for drugmakers to develop strain-specific vaccines.

The real-world efficacy data will help determine whether a new vaccine that specifically targets omicron is needed, Bourla said. The companies would be able to produce very large quantities of such a shot by March, he said.

Read More: Third Dose of Pfizer-BioNTech Shot Key to Fight Elusive Omicron

Meanwhile, Pfizer is also making headway on bringing its experimental Covid-19 antiviral treatment to market. The company expects to provide final clinical trial results to U.S. regulators “within several days,” Bourla said. Pfizer has already shared interim results with the Food and Drug Administration that show the pill, Paxlovid, reduced risk of hospitalization or death by 89% among high-risk people who contracted Covid.

Merck & Co.’s competing drug candidate showed a significant drop in efficacy between its interim and final analyses, and the FDA has asked Pfizer for more data on its pill. Still, Bourla said he’s optimistic that regulators could make a decision on Paxlovid before the end of the year.

(Updates with CEO comments in second paragraph.)

–With assistance from David Westin and Robert Langreth.

© 2021 Bloomberg L.P.
Gallery

Comments - share your knowledge and experience

Please note you must be a Maverick Insider to comment. Sign up here or sign in if you are already an Insider.

Everybody has an opinion but not everyone has the knowledge and the experience to contribute meaningfully to a discussion. That’s what we want from our members. Help us learn with your expertise and insights on articles that we publish. We encourage different, respectful viewpoints to further our understanding of the world. View our comments policy here.

No Comments, yet

Please peer review 3 community comments before your comment can be posted